BPC-157 vs TB-500: Research Comparison

BPC-157 vs TB-500: How the Research Compares

BPC-157 and TB-500 are the two peptides most often studied for tissue repair, and they are often stocked side by side or as a blend. They are unrelated molecules, however, with different origins, different proposed mechanisms and very different bodies of evidence. This page compares them using the published research, with links to the source papers on PubMed. AurumLabs supplies both, and a combined blend, for in-vitro laboratory research only, so nothing here is a claim about our material’s effects in humans.

The short answer

  • BPC-157 is a 15-amino-acid peptide derived from a protein found in gastric juice. Most of its literature comes from one research group and from rodent and cell studies, covering tendon, gut and wound models.
  • TB-500 is a short synthetic fragment of thymosin beta-4, a 43-amino-acid protein that binds actin. Most of the research cited for it was done on full-length thymosin beta-4, not on the fragment itself.
  • Neither is an approved medicine, and neither has large controlled human trials. Both are on the World Anti-Doping Agency prohibited list.

Side-by-side comparison

BPC-157 TB-500
Origin Partial sequence of body protection compound, a protein in human gastric juice Synthetic fragment of thymosin beta-4, an actin-binding protein found in most cells
Length 15 amino acids 7 amino acids (Ac-LKKTETQ, the actin-binding region); full thymosin beta-4 is 43
Sequence GEPPPGKPADDAGLV Ac-LKKTETQ
CAS number 137525-51-0 Not consistently assigned for the fragment (full thymosin beta-4: 77591-33-4)
Molecular formula C62H98N16O22 C38H68N10O14
Molecular weight 1419.5 g/mol 889.0 g/mol
Main research models Tendon and ligament, gastrointestinal lining, skin wounds Skin and corneal wounds, cardiac repair (mostly full thymosin beta-4)
Proposed mechanisms Angiogenesis, nitric oxide signalling, fibroblast migration Actin sequestration, cell migration, angiogenesis
Human evidence Very limited; no large controlled trials Small trials of full thymosin beta-4 only; none of the fragment
WADA status Prohibited (S0, non-approved substances) Prohibited
AurumLabs vial sizes 5mg, 10mg 2mg, 5mg, 10mg

How they differ in origin

BPC-157 stands for body protection compound 157. It is a stable 15-amino-acid sequence taken from a larger protein isolated from human gastric juice. It is notably stable in gastric acid, which is one reason it has been studied so heavily in gut models.

TB-500 is a synthetic peptide based on thymosin beta-4. The full protein is one of the most abundant actin-binding proteins in cells and is involved in cell movement. TB-500 as sold for research is usually the short acetylated sequence LKKTETQ, which corresponds to the protein’s central actin-binding region. That matters because a fragment cannot be assumed to reproduce everything the full protein does.

What the BPC-157 research shows

Most published BPC-157 work comes from Predrag Sikiric’s group in Zagreb. Rat studies report faster tendon healing (Chang 2011) and protective effects across gastrointestinal injury models (Sikiric 2011). Reviews in 2019 and 2021 summarised effects in musculoskeletal and wound models. Two 2025 reviews in orthopaedic journals concluded that the animal data are consistent but that controlled human evidence is still missing, and that safety in humans has not been established. Read more in our BPC-157 research overview.

What the TB-500 and thymosin beta-4 research shows

Full-length thymosin beta-4 accelerated wound closure in rodent skin (Malinda 1999) and corneal injury models (Sosne 2001), and a 2004 Nature paper reported cardiac repair effects in mice (Bock-Marquette 2004). Later work challenged parts of the cardiac story: a 2012 knockout study found thymosin beta-4 was not required for normal heart development, and another 2012 study found no true myocardial regeneration after treatment. Almost none of this work used the short TB-500 fragment. Read more in our TB-500 research overview.

Why they are studied together

Because the two peptides are thought to act through different routes, researchers interested in repair models sometimes compare them or use them in combination. There is little published work on the combination itself. AurumLabs stocks a BPC-157 + TB-500 blend in one vial for laboratories that want both.

Sourcing for laboratory research

AurumLabs holds both peptides in UK stock as lyophilised powder in sealed vials, tested independently by HPLC and mass spectrometry, with batch Certificates of Analysis on our Certificates page. Prices for every vial size are on the price list, and the price comparison shows how each compares with well-known UK suppliers.

These compounds are sold for in-vitro laboratory research only. They are not medicines or supplements and are not for human or animal consumption.

References

  1. Chang CH et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing. J Appl Physiol, 2011. PMID: 21030672
  2. Sikiric P et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des, 2011. PMID: 21548867
  3. Gwyer D et al. Gastric pentadecapeptide BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res, 2019. PMID: 30915550
  4. Seiwerth S et al. Stable gastric pentadecapeptide BPC 157 and wound healing. Front Pharmacol, 2021. PMID: 34267654
  5. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J, 2025. PMID: 40756949
  6. Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Curr Rev Musculoskelet Med, 2025. PMID: 40789979
  7. Malinda KM et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol, 1999. PMID: 10469335
  8. Sosne G et al. Thymosin beta 4 promotes corneal wound healing and modulates inflammatory mediators in vivo. Exp Eye Res, 2001. PMID: 11311052
  9. Bock-Marquette I et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature, 2004. PMID: 15565145
  10. Banerjee I et al. Thymosin beta 4 is dispensable for murine cardiac development and function. Circ Res, 2012. PMID: 22158707
  11. No muscle for a damaged heart: thymosin beta 4 treatment after myocardial infarction does not induce myocardial regeneration. J Mol Cell Cardiol, 2012. PMID: 22019445